|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
<b>:</b> The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits.
|
31416288 |
2019 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer.
|
29295876 |
2018 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
(2018) report that chondroitin-4-sulfate, which is found in a common supplement meant to alleviate degenerative joint disorders, promotes the growth of BRAF V600E mutant melanoma.
|
29547718 |
2018 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
21 (78%, 57·7-91·4) of 27 patients with Val600Glu BRAF-mutant melanoma responded and 15 (56%, 35·3-74·5) had a confirmed response.
|
22608338 |
2012 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanoma cell lines expressing (WT)B-Raf and (WT)Ras grew with similar proliferation rates, showed constitutive activation of ERK1/2, and had similar levels of B-Raf expression and B-Raf kinase activity as melanoma cell lines expressing the activating V600E mutation ((V600E)B-Raf).
|
16452469 |
2006 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanoma cell lines with RETp, RET wild type (RETwt), BRAF V600E mutation (BRAFmt) or BRAF wild type (BRAFwt) were assessed for functional activity.
|
19561646 |
2009 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
|
21107323 |
2010 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.
|
22395615 |
2012 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Knockdown of Apollon, by siRNA, triggered apoptosis and/or significantly enhanced melanoma cell death in response to cytotoxic drugs, MEK- and BRAF(V600E)-specific inhibitors, and soluble or membrane-bound TRAIL.
|
22553342 |
2012 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanomas that contain B-RAF(V600E) mutations respond transiently to RAF and MEK inhibitors; however, resistance to these agents remains a formidable challenge.
|
23737487 |
2013 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanomas harboring the BRAF V600E mutation have demonstrated sensitivity to both RAF and MAPK/extracellular signal regulated kinase (ERK) inhibitors in vitro and in vivo.
|
24077403 |
2013 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanomas express PD-L1 in association with tumor-infiltrating lymphocytes (TIL), but the potential contribution of the BRAF V600E mutation (BRAFmut) to induced PD-L1 expression has not been determined.
|
25370533 |
2015 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanoma lymph node metastases were d</span>iagnosed in 21.8% (12/55) of the sentinel nodes, and BRAF V600E immunopositivity was detected in 34.5% (19/55) of the cases.
|
25442222 |
2015 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanomas harboring BRAF mutation (V600E) are known to recur frequently following treatment with BRAF inhibitors (BRAFi) despite a high initial response rate.
|
29094484 |
2017 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanoma cell line A375 with BRAF V600E point mutation exhibits higher FRET efficiency than liver cancer cell line HegG2 that was not reported having the mutation at this point.
|
29766713 |
2018 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanoma treatment with the BRAF V600E inhibitor vemurafenib provides therapeutic benefits but the common emergence of drug resistance remains a challenge.
|
30010109 |
2018 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
V600E was the only identified mutation type; 35.4% of primary vs. 18.9% of metastatic melanomas.
|
25236573 |
2014 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
V600E was the predominant mutation in 21/24 (87.5%) of primary and 23/25 (92%) of metastatic melanomas.
|
25262755 |
2014 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A 39-year-old white male was treated with vemurafenib, cobimetinib, and atezolizumab for a stage IV (T0, N3, M1) BRAF-V600E mutated malignant melanoma in the context of a clinical trial.
|
31157737 |
2020 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A 49-year-old man initially diagnosed in 1995 with cutaneous melanoma presented to the authors' institution in 2009 with metastatic, BRAF V600E-mutant melanoma.
|
24616537 |
2014 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A 61-year-old man was diagnosed with stage IIIB BRAF V600E mutant melanoma in October 2012.
|
26512791 |
2015 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A combined inhibition strategy targeting BRAF together with multiple erbB family kinases is potentially beneficial for treating BRAF V600E mutant melanoma.
|
24709886 |
2014 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
|
27488807 |
2016 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A high percentage of both melanomas and papillary carcinomas of the thyroid harbors a recurrent mutation (i.e., BRAF(V600E) ) in the BRAF oncogene.
|
24574369 |
2014 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A novel RFLP-ARMS TaqMan PCR-based method for detecting the BRAF V600E mutation in melanoma.
|
30008844 |
2018 |